SLC5A7 GENETIC MARKERS ASSOCIATED WITH AGE OF ONSET OF ALZHEIMER'S DISEASE

Haplotypes in the SLC5A7 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these SLC5A7 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	REED, CAROL R, BRAIN, CARLOS, DAIN, BRADLEY, ATHANASIOU, MARIA, AERSSENS, JEROEN, DENTON, REX, R, OZDEMIR, VURAL, COHEN, NADINE, JUDSON, RICHARD S
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Haplotypes in the SLC5A7 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these SLC5A7 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these SLC5A7 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile. L'invention concerne des haplotypes dans le gène SLC5A7 associés à l'âge de l'apparition de la maladie d'Alzheimer. L'invention concerne également des compositions et des méthodes de détection et d'utilisation de ces haplotypes SLC5A7 dans diverses applications cliniques. Parmi ces applications, on peut citer des produits manufacturés comprenant des composés efficaces pour retarder l'âge de l'apparition de la maladie d'Alzheimer chez des individus à risque et présentant un de ces haplotypes SLC5A7, des procédés et des kits de prédiction de l'âge de l'apparition de la maladie d'Alzheimer chez un individu à risque en fonction de son profil d'haplotype, et des méthodes qui permettent de retarder l'âge de l'apparition de la maladie d'Alzheimer chez des individus à risque en fonction de leur profil d'haplotype.